UBS’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

UBS’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$47K	Buy	3,800 +800	+27%	+$9.3K	﹤0.01%	6921
2014 Q2	$47K	Sell	3,000 -27,000	-90%	-$385K	﹤0.01%	6963
2014 Q1	$454K	Buy	30,000 +3,700	+14%	+$41.8K	﹤0.01%	4339
2013 Q4	$200K	Buy	26,300 +18,300	+229%	+$98.7K	﹤0.01%	5291
2013 Q3	$27K	Buy	8,000 +3,000	+60%	+$7.91K	﹤0.01%	7684
2013 Q2	$12K	Buy	+5,000	New	+$12K	﹤0.01%	8474

Other funds holding HZNP

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

MRM

Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS's HZNP Position: Q3 2014 in Review

UBS reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 5.8% in Q3 2014, selling an estimated $132K and leaving 182,733 shares worth $2.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2801.

UBS first reported a position in HZNP in Q2 2013 and has held it in 6 quarters since. The position peaked at $3.07M in Q2 2014. 120 funds tracked by Wall St. Rank hold HZNP as of Q3 2014.

UBS held 182,733 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $2.24M as of Q3 2014.
UBS sold 11,336 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2014, an estimated $132K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2801 holding.
UBS first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and has held it in 6 quarters since.
UBS's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.07M in Q2 2014.
120 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.